Skip to main content

Table 2 Evolution of imiglucerase dose during the supply constraint period

From: Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1

 

Dose of imiglucerase (U/kg/4-weeks)

Change from pre-constraint dose (U/kg/4-weeks)

n

Mean (SD)

Median (range)

n

Mean (SD)

Median (range)

Pre-constraint (in the 6 months prior to first modification)

94

92.5 (33.5)

92 (10; 239)

   

First modification on or after 01 Jun 2009

99

35.0 (32.0)

40 (0; 181)

94

−55.9 (28.9)

−52 (−127; −6)

Time interval after the first modification:

3 months

98

17.5 (29.4)

0 (0; 160)

93

−74.1 (38.6)

−69 (−223; 0)

6 months

95

41.0 (42.8)

49 (0; 160)

91

−51.1 (51.6)

−51 (−223; 62)

9 months

95

55.9 (45.0)

56 (0; 170)

90

−36.6 (48.1)

−29 (−223; 62)

12 months

96

37.3 (45.5)

0 (0; 129)

91

−55.8 (52.2)

−60 (−223; 62)

Last modification prior to 01 Nov 2010

98

37.6 (47.3)

0 (0; 160)

93

−56.2 (49.7)

−64 (−130; 62)

  1. n: number of patients with available data; SD: standard deviation; Range: minimum; maximum.